Alexandria lifts profit target to EGP 690 million for Alexandria Pharmaceuticals stock

Published on 10/01/2026 at 12:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Profit reached EGP 524.80 million in fiscal 2025/2026, up 34.16 percent. Alexandria Pharmaceuticals stock had EGP 6.1 billion value on September 30, 2026.

AXPH, EGS38341C011, Illustration mit AI erstellt.

Alexandria Company for Pharmaceuticals and Chemical Industries (EGS38341C011) set a fiscal 2026/2027 net profit target of EGP 690.00 million on September 21, 2026, up from the EGP 660.00 million target approved for the current fiscal year, according to Alborsa News. The target gives the company a quantified earnings benchmark as it expands production capacity and renews equipment.

Profit growth supports higher target

The company reported fiscal 2025/2026 net profit of EGP 524.80 million, compared with EGP 391.17 million in the prior fiscal year. That represents growth of 34.16 percent, according to Amwal Al Ghad on September 21, 2026.

Sales increased to EGP 3.18 billion from EGP 2.76 billion in fiscal 2025/2026, a 15.24 percent gain. The combination of higher sales and profit provides the operating basis for the next budget, although the EGP 690.00 million target remains a plan rather than a reported result.

Sales plan includes new capacity

Alexandria Pharmaceuticals also set a fiscal 2026/2027 revenue target of EGP 3.70 billion, compared with EGP 3.67 billion approved for the current fiscal year. The planned increase is smaller than the prior year's sales growth, making execution and margin delivery important measures for the new budget.

The company allocated EGP 95.15 million for self-financed investment in fiscal 2026/2027. The spending is intended for new machinery, production-capacity improvements, equipment renewal and rehabilitation of warehouses and packaging facilities, according to Alborsa News.

EGX valuation and market range

Alexandria Pharmaceuticals was last quoted at EGP 1,442.15 on the Egyptian Exchange on September 30, 2026 at 7:45 p.m. EEST. The same market snapshot showed an EGP 6.1 billion market capitalization and a 52-week range of EGP 700.00 to EGP 1,708.00, putting the latest quote EGP 265.85 below the yearly high.

The company is listed on the Egyptian Exchange under AXPH.EG in the Health Technology sector, with pharmaceuticals as its core activity, according to MyStocks Africa. For investors, the key numerical test is whether the planned EGP 690.00 million profit can build on the EGP 524.80 million achieved in fiscal 2025/2026.